aldo-keto

AKR1C3-IN-4, a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.56 μM, shows potential for castrate-resistant prostate cancer (CRPC) research.

m-Anisaldehyde exhibits binding activity toward aldo-keto reductase family 1 member A1 and is widely used in biochemical experiments and drug synthesis research.

Phenethyl trans-cinnamate is an aromatic ester found in various plants. It is an important intermediate in the synthesis of various drugs and spices, and is also used in the synthesis of various flavors, fragrances and cosmetics.

AKR1C3-IN-9, a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50 = 8.92 nM), can significantly reverse Doxorubicin (DOX) resistance in a resistant breast cancer cell line.

S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research.

AKR1Cs-IN-1 (Compound 29) is an effective and broad-spectrum inhibitor of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). It achieves subtype inhibition by simultaneously binding to the SP2 and SP3 pockets, thereby blocking metabolic pathways related to drug resistance. In enzyme assays, AKR1Cs-IN-1 exhibits significant inhibitory activity with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM for AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. The compound shows excellent resensitizing effects in doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, effectively enhancing the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on breast cancer resistance.

RJG-2051 is a selective covalent inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), with an IC50 value of 13 nM. It interferes with the metabolism of substrates such as androgens, estrogens, and prostaglandins through AKR1C3. RJG-2051 holds potential for cancer research.

OBI-3424, a highly selective prodrug, is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent.

SN34037 is a specific Aldo-keto reductase 1C3 (AKR1C3) inhibitor capable of reducing PR-104A to PR-104H and inhibiting the cytotoxic activity of PR-104A, suitable for studying PR-104A-responsive leukaemia.

MDK-0738 is a potent and selective aldo-keto reductase 1C3 inhibitor.

AKR1B10-IN-1, a powerful AKR1B10 (Aldo-Keto Reductase 1B10) inhibitor, demonstrates an IC50 value of 3.5 nM. This compound effectively curtails the proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells.

Obafistat is a potent inhibitor of aldo-keto reductase AKR1C3 with an IC50 of 1.2 nM for human AKR1C3.

S07-2009 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.20 μM [1].

S07-2001 enhances Doxorubicin against cancer cells activity, which can be used as a chemotherapeutic potentiator for cancer drug resistance. S07-2001 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC 50 value of 2.08 μM [1].

S07-2005 racemic is a chemically potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. Due to its inhibitory properties, it exhibits potential as a chemotherapeutic potentiator, specifically in the context of overcoming drug resistance in cancer [1].

S07-2008 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3) (IC50: 0.16 μM) and has anticancer effects.

Obafistat Na is an aldo-keto reductase AKR1C3 inhibitor.

S07-1066, an aldo-keto reductase 1C3 (AKR1C3) inhibitor, enhances doxorubicin (DOX) cytotoxicity by selectively inhibiting AKR1C3-mediated reduction of DOX and reversing DOX resistance in cells with elevated AKR1C3 expression [1].

AKR1C3-IN-12 (compound 2j), an inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibits potent activity with an IC50 of 27 nM. It has been shown to enhance the effectiveness of Gemcitabine and Cisplatin in treating bladder cancer [1].

7-O-Methylluteone is a hydroxylated isoflavone, specifically a derivative of luteone where the 7-position hydroxyl group is replaced by a methoxy group. It functions as an EC (aldo-keto reductase) inhibitor and acts as a metabolite.